Výsledky vyhledávání - "Yu V, Makarova"

Akademický článek

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia

Autor: N. A. Avxentyev, Yu. V. Makarova, A. S. Makarov

Publikováno v: Опухоли женской репродуктивной системы, Vol 20, Iss 2, Pp 55-65 (2024)

Background. Reducing malignant mortality to 185 cases per 100,000 by 2030 is one of goals of the state program “Healthcare development” in Russia.Aim. To assess potential impact of using trastuzumab deruxtecan in patients with breast cancer on re

Externí odkaz: https://doaj.org/article/2ea8bc264d5d4000aea5b00788b94060

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia

Autor: N. A. Avxentyev, Yu. V. Makarova

Publikováno v: Фармакоэкономика, Vol 16, Iss 3, Pp 375-385 (2023)

Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable BRAF V600-mutated melanoma in the Russian Federation. Material and methods. The comparators

Externí odkaz: https://doaj.org/article/b7161eca3201443dabc3216b363b15b4

Zobrazit plný text záznamu

Akademický článek

Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation

Autor: N. A. Avxentyev, Yu. V. Makarova

Publikováno v: Фармакоэкономика, Vol 15, Iss 3, Pp 309-318 (2022)

Background. Diabetic nephropathy (DN) is a specific kidney lesion in patients with diabetes mellitus, which leads to the development of endstage kidney disease and requires substitutive renal therapy (dialysis or transplantation). Canagliflozin is a

Externí odkaz: https://doaj.org/article/0ee83679dd0649838a42445a68dfe0be

Zobrazit plný text záznamu

Akademický článek

Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy

Autor: N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev

Publikováno v: Фармакоэкономика, Vol 14, Iss 4, Pp 451-461 (2022)

Background. New pathogenetic treatment options, such as gene therapy, are now used to treat previously uncurable diseases. However, price of such treatment is high, especially in the case of orphan diseases, where costs may many-fold exceed the price

Externí odkaz: https://doaj.org/article/697af79c570746cea190751ae2c2aec4

Zobrazit plný text záznamu

Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer

Autor: N. A. Avxentyev, M. Yu. Frolov, Yu. V. Makarova

Publikováno v: Onkourologiâ, Vol 16, Iss 2, Pp 82-96 (2020)

Background. Prostate cancer is one of the most common malignant diseases among men. Until recently, the most common treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) in Russia was to continue previously started hormonal therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f97149a4fa74922ee033c3a221820043
https://oncourology.abvpress.ru/oncur/article/view/1344

Zobrazit plný text záznamu

Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer

Autor: N. A. Avxentyev, M. Yu. Frolov, Yu. V. Makarova

Publikováno v: Onkourologiâ, Vol 15, Iss 2, Pp 86-99 (2019)

Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a3dfc1c431737cfe78aa4e16e3dff4
https://oncourology.abvpress.ru/oncur/article/view/958

Zobrazit plný text záznamu

Dynamics of abdominal pain syndrome in patients with cholelithiasis throughout the 10-year follow-up period

Autor: N V Litvinova, N.B. Voloshinа, Yu . V. Makarova, M F Osipenko

Publikováno v: JOURNAL of SIBERIAN MEDICAL SCIENCES. :54-66

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e7c60a88ec65a9b3ec08b524a2ca6db
https://doi.org/10.31549/2542-1174-2018-4-54-66

Zobrazit plný text záznamu

THE FREQUENCY OF DYSPEPTIC DISORDERS FOLLOWING CHOLECYSTECTOMY PATIENTS ACCORDING TO THE 10-YEAR STUDY

Autor: Yu V, Makarova, N V, Litvinova, M F, Osipenko, N B, Voloshina, Yu A, Frolov

Publikováno v: Eksperimental'naia i klinicheskaia gastroenterologiia = Experimentalclinical gastroenterology. (9)

To evaluate gastrointestinal symptoms during 10 years after cholecystectomy in patients with symptomatic and asymptomatic gallstone disease and to identify predictors of them.The work is the part of a prospective long-term monitoring of patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3286e246372b0963f98e7c24b837b992
https://pubmed.ncbi.nlm.nih.gov/29889395

Zobrazit plný text záznamu

The gastroenterological symptoms and the quality of life of the patients during the late postoperative period following cholecystectomy for the treatment of cholelithiasis

Autor: Yu . V. Makarova, M F Osipenko, N B Voloshina, N V Litvinova

Publikováno v: Dokazatel'naya gastroenterologiya. 3:3

prior to surgery (95% CI 0.627—0.373; p=0.0001), diarrhea (32.9% versus 2.9%, 95% CI 0.410—0.190; p=0.0001), and constipation (44.3% versus 17.1%, 95% CI 0.423—0.120; p=0.001). The parameters of QL characterizing the physical health status of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::162ab41ff5bf586873515f756c48806c
https://doi.org/10.17116/dokgastro2014343-7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání